Sigilon Therapeutics’ encapsulated cell therapy for hemophilia A has hit a regulatory snag as the FDA has hit the stop button on its phase 1/2 study after a patient developed a serious side effect that caused their body to attack the treatment.
Muna Therapeutics has raised $73 million to develop small-molecule treatments for Alzheimer’s and other neurodegenerative diseases. The series A will bankroll work on drugs to repair neuronal dysfunction, resolve neuroinflammation and restore neuroprotection and resilience to disease.
After Ovid Therapeutics’ lead product failed a phase 3 clinical trial in April, CEO Jeremy Levin knew they had some tough work ahead of them. Now, the biotech has announced a leadership shuffle and staff reductions as it pivots to focus on early-stage development.
St. Jude Medical, Alere pay combined $65M to settle DOJ claims they knowingly sold defective devices
The U.S. Department of Justice (DOJ) collected two separate settlements from medical device makers after the government said they continued to sell defective products for years amid receiving reports of injuries and deaths linked to their hardware.
As Verge Genomics plugs away at its amyotrophic lateral sclerosis (ALS) program, it is teaming up with Eli Lilly to pursue even more targets for new treatments against the devastating disease.
Ophthalmic device developer Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO.
Armed with a recent breakthrough designation from the FDA for its tumor-destroying radiation technology, Alpha Tau Medical is plowing ahead with plans to go public before the end of the year.
As pharmaceutical manufacturing grows increasingly complex, Merck KGaA wants to ramp up its development capabilities for clinical trial compounds.
Nuvalent has brought in $185 million through two funding rounds since launching in January, but the precision cancer biotech wants more: an IPO.
On the heels of a $62 million funding round, Denmark’s Adcendo has a new CEO: Michael Pehl, formerly Celgene’s oncology chief and CEO of Immunomedics, the company behind Gilead’s potential blockbuster breast cancer drug Trodelvy.